Acalabrutinib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 768 publications

Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.

Pathophysiological Drivers of Mast Cell Activation Syndrome and Implications for Treatment.

Journal: Fortune journal of health sciences
Published: August 13, 2026

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 07, 2026

Sonrotoclax (Beqalzi) for mantle cell lymphoma.

Sonrotoclax (Beqalzi) for mantle cell lymphoma.

Journal: The Medical letter on drugs and therapeutics
Published: July 14, 2026

Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease.

Acalabrutinib for Treatment of Steroid-Refractory Chronic Graft Versus Host Disease.

Journal: Transplantation and cellular therapy
Published: July 08, 2026

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.

BTK Inhibitors for the Treatment of Mantle Cell Lymphoma-Current Status and Perspectives.

Journal: Cancers
Published: July 08, 2026

Acute Kidney Injury Due to Granulomatous Interstitial Nephritis as the Initial Presentation of CLL/SLL Treated with Acalabrutinib.

Acute Kidney Injury Due to Granulomatous Interstitial Nephritis as the Initial Presentation of CLL/SLL Treated with Acalabrutinib.

Journal: Internal medicine (Tokyo, Japan)
Published: July 05, 2026

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Real-world comparative effectiveness of first-line BTK inhibitors in chronic lymphocytic leukemia.

Journal: Future oncology (London, England)
Published: June 30, 2026

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Journal: Leukemia & lymphoma
Published: June 24, 2026

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Journal: Leukemia & lymphoma
Published: June 21, 2026

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

Journal: Expert opinion on drug discovery
Published: June 15, 2026

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis.

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis.

Journal: Cureus
Published: June 03, 2026

All-oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL: Phase 3 AMPLIFY trial results show significantly improved progression-free survival in comparison with standard chemoimmunotherapy.

All-oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL: Phase 3 AMPLIFY trial results show significantly improved progression-free survival in comparison with standard chemoimmunotherapy.

Journal: Cancer
Published: June 02, 2026
Showing 1-12 of 768

Last Updated: 09/26/2026